🧬 Aging Wiki

lpl

Properties1
aliaseslipoprotein lipase, LIPL_HUMAN, LIPD, LPL

14 min read

LPL (Lipoprotein Lipase)

Lipoprotein lipase is the rate-limiting enzyme of plasma triglyceride hydrolysis — the gatekeeping step between liver-derived and gut-derived lipoproteins and peripheral tissue energy delivery. Synthesized in adipocytes, myocytes, and cardiomyocytes, LPL is transported to the luminal surface of capillary endothelium by gpihbp1, where it cleaves triglyceride cores from chylomicrons and VLDL into free fatty acids for tissue uptake. LPL loss-of-function causes familial chylomicronemia syndrome (FCS), the classical Mendelian severe hypertriglyceridemia. Genetic and Mendelian-randomization evidence confirms LPL gain-of-function is cardioprotective. A wave of novel APOC3-targeting and ANGPTL3-targeting drugs acts primarily by removing inhibition of endogenous LPL, repositioning this enzyme as a key therapeutic node in cardiovascular aging 12.

Identity

  • UniProt: P06858 (LIPL_HUMAN) — Swiss-Prot reviewed, accessed 2026-05-09
  • NCBI Gene: 4023
  • HGNC: 6677 (symbol: LPL; synonym: LIPD)
  • Ensembl: ENSG00000175445
  • Chromosomal location: 8p21.3
  • Length: 475 aa precursor; signal peptide residues 1–27 → 448 aa mature protein
  • Catalytic class: Serine hydrolase; EC 3.1.1.34 (triglyceride lipase; primary) + EC 3.1.1.32 (phospholipase A1; secondary)
  • Mouse ortholog: Lpl (one-to-one; high conservation; LPL KO mouse is a key mechanistic model)
  • GenAge entry: not listed in GenAge-human as of 2026-05-09 needs-canonical-id (LPL is not curated in GenAge-human despite its well-established role in age-related CV risk; the human GenAge database focuses primarily on transcription factors and signaling proteins, and this lipase may warrant a future curation request)

Function

LPL operates at the luminal surface of capillary endothelium in muscle, adipose, heart, and other tissues. The canonical mechanism 3:

  1. Synthesis — LPL is produced in parenchymal cells (adipocytes, myocytes, cardiomyocytes, macrophages) — notably NOT in the endothelial cells where it functions.
  2. Transport to the capillary lumen — Secreted LPL is captured by GPIHBP1 (GPI-anchored HDL-binding protein 1, produced by endothelial cells), which transports LPL across the endothelium to anchor it on the luminal surface. GPIHBP1 mutations cause an FCS-like syndrome by preventing LPL from reaching its site of action.
  3. Lipolysis — Circulating chylomicrons and VLDL (whose triglyceride-rich cores were assembled with apob-48 and apob-100 respectively) dock on luminal LPL, which hydrolyzes ester bonds in the TG core → 3 free fatty acids + 2-monoacylglycerol. Free fatty acids enter underlying cells: adipocytes re-esterify for storage; myocytes and cardiomyocytes oxidize for fuel.
  4. Particle remodeling — TG-depleted chylomicron remnants and VLDL remnants (IDL) are released back into circulation, enriched in cholesterol esters and ApoE. These remnants are taken up by liver LRP1 and ldlr, or accumulate as atherogenic substrates if clearance is impaired.

Activators and inhibitors

LPL activity is tightly regulated by apolipoproteins and the ANGPTL family:

RegulatorTypeMechanismCV consequence of LOF
ApoC-IIActivator (required cofactor)Direct allosteric activation via conformational shift 4ApoC-II LOF → severe hypertriglyceridemia (rare)
ApoA-VActivator (modest)Bridges lipoproteins to HSPG/LPL on endotheliumApoA-V rare variants → hypertriglyceridemia
ApoC-IIIInhibitorDose-dependent inhibition; also displaces ApoC-II; independently inhibits remnant clearance by ldlr/LRP1APOC3 LOF → low TG, reduced CV risk (MR signal) 5
ANGPTL3InhibitorInhibits LPL activity (distinct from ANGPTL4 mechanism) 6ANGPTL3 LOF → combined hypotriglyceridemia + hypolipidemia
ANGPTL4InhibitorInactivates LPL by inducing dissociation of the active dimer into inactive monomers 6ANGPTL4 E40K → lower TG, CHD risk
ANGPTL8Context-dependentForms complexes with ANGPTL3/ANGPTL4; redistributes LPL activity between fasting and fed statesUnder investigation

Mendelian-randomization and genetic evidence

The causal chain from LPL activity → triglycerides → ASCVD is among the best-established in lipid genetics [^mr-causal-evidence: yes]:

  • LPL Ser447Stop (S447X) — the most common functional LPL variant (~20% minor allele frequency in Europeans per population-level estimates). Truncates the terminal 2 amino acids. Modest gain of function in enzymatic activity. Xie 2017 meta-analysis (14 case-control studies, n=1,519 cases / 824 controls) found no significant CAD risk reduction per allele (OR 1.04, 95% CI 0.60–1.80, p=0.90); only the rare homozygous XX genotype was significantly associated with increased CAD risk (OR 2.37, 95% CI 1.33–4.24, p=0.004) — an unexpected direction interpreted cautiously given high heterogeneity (I²=53%) and publication bias in that subgroup 7. The widely-cited per-allele cardioprotective effect (~10% lower CHD risk) derives from larger GWAS consortia data rather than Xie 2017 specifically. contradictory-evidence
  • LPL loss-of-function (compound heterozygous / homozygous) → FCS phenotype (see below).
  • APOC3 loss-of-function — Heterozygous carriers of rare APOC3 LOF variants (nonsense, splice-site, missense; ~1 in 150 persons of European ancestry) have ~39% lower TG and ~40% lower CHD risk (OR 0.60; 95% CI 0.47–0.75) across 110,970 participants in 15 studies 5. Consistent with LPL disinhibition being the proximate mechanism.
  • ANGPTL3 LOF — associated with lower TG + lower LDL + reduced CAD, providing genetic validation of the LPL-axis as druggable for CV risk.
DimensionStatusNotes
LPL pathway conserved in humans?yesEnzyme, GPIHBP1-anchoring, ANGPTL regulation all conserved
CV phenotype conserved?yesMR instruments validate TG → ASCVD causality in humans
Replicated in humans?yesMultiple LOF/GOF variant studies + Phase 3 trials of LPL-axis drugs

Role in aging

LPL is not a classic longevity gene (not in GenAge-human), but it is central to the cardiovascular aging risk axis:

  • Postprandial hypertriglyceridemia — LPL activity, and the efficiency of chylomicron and VLDL TG hydrolysis, declines modestly with age in some tissues. Older individuals show prolonged postprandial hypertriglyceridemia — elevated circulating remnant particles after meals [^lipoprotein-metabolism]. Remnant cholesterol (chylomicron and VLDL remnants) enters arterial intima and contributes to foam-cell formation in the same manner as LDL; this pathway is now recognized as an independent atherogenic mechanism complementary to the ApoB/ldlr axis. needs-replication (robust age-stratified human data on LPL activity decline remain limited)
  • Adipose tissue metabolic shift — In obese and metabolically dysregulated older individuals, adipose LPL activity is reduced and hepatic lipase activity increased — tilting TG partitioning toward smaller, denser LDL particles and raising atherogenic risk beyond what fasting TG levels indicate.
  • ApoC-III as an inflammation-responsive LPL inhibitor — ApoC-III levels rise with insulin resistance and metabolic syndrome, which are both age-associated. This creates a feed-forward loop: aging → insulin resistance → elevated ApoC-III → reduced LPL activity → higher TG + remnants → more ASCVD.
  • Indirect link to senescence — Foam cells (macrophages laden with lipid from TG-rich remnants) undergo cellular-senescence within plaques, contributing SASP cytokines. This makes LPL-mediated TG flux an upstream driver of vascular inflammaging, linking to the altered-intercellular-communication and chronic-inflammation hallmarks.

Familial chylomicronemia syndrome (FCS)

LPL homozygous or compound-heterozygous loss-of-function causes FCS — the canonical severe Mendelian hypertriglyceridemia:

  • Fasting TG: often >1000–2000 mg/dL (normal < 150 mg/dL); plasma visibly lipemic
  • Complications: recurrent acute pancreatitis (can be life-threatening), eruptive xanthomas, lipemia retinalis
  • Prevalence: ~1:1,000,000 (true LPL LOF); the broader “multifactorial chylomicronemia” phenotype is ~100-fold more common
  • Standard TG-lowering drugs are ineffective in true FCS — fibrates, fish oil, and niacin all require some residual LPL activity to work. Treatment pillars are: severe fat restriction (<10–15% kcal from fat; including medium-chain TG supplementation), plus novel RNA-targeting therapies that reduce ApoC-III (see below)
  • Alipogene tiparvovec (Glybera) — AAV-LPL gene therapy, EU-approved 2012, then withdrawn due to limited market uptake; first gene therapy approved in the West. A successor AAV5-LPL gene therapy (NCT05860569) is now in Phase 2/3 in China for LPL-deficient patients with recurrent pancreatitis.

Pharmacological landscape

LPL activity can be enhanced by four pharmacological strategies targeting the inhibitory regulators:

1. Fibrates — PPARα-mediated LPL upregulation

Fibrates (gemfibrozil, fenofibrate, bezafibrate) are PPARα agonists that transcriptionally upregulate LPL expression in muscle and adipose, increasing TG hydrolysis. They also downregulate ApoC-III. Net effect: ~30–50% TG reduction. CV outcome benefit is modest and primarily seen in subgroups with high TG / low HDL (ACCORD-Lipid, Helsinki Heart Study subgroup). FDA-approved; well-established safety profile.

2. Omega-3 fatty acids — LPL activation + VLDL suppression

High-dose omega-3 FAs (EPA, DHA) work via multiple mechanisms: activating PPARα → LPL upregulation; reducing hepatic VLDL secretion; activating LPL directly. The EPA-vs-DHA controversy is unresolved:

  • REDUCE-IT (n=8,179; icosapent ethyl [EPA-only] 4 g/d vs mineral-oil placebo; statin-background; TG inclusion range 135–499 mg/dL; median baseline TG ~216 mg/dL per full paper — not confirmable from abstract alone): 25% relative reduction in MACE (CV death, MI, stroke, revascularization, unstable angina); HR 0.75 (95% CI 0.68–0.83); p<0.001 1. However, the mineral-oil placebo control is contested — some argue the control raised LDL-C in the placebo arm, inflating apparent benefit 8. contradictory-evidence
  • STRENGTH (n=13,078; omega-3 carboxylic acid [EPA+DHA] 4 g/d vs corn oil placebo; similar statin-background; median baseline TG ~240 mg/dL): no MACE benefit (HR 0.99 [95% CI 0.90–1.09]); p=0.84; trial terminated early for futility 9. Corn oil placebo considered “active” by some due to minor LDL-raising. The EPA vs mixed-ω3 mechanistic discordance remains unresolved. contradictory-evidence

Neither REDUCE-IT nor STRENGTH definitively isolates LPL activation as the mechanism of any CV benefit; anti-platelet, anti-inflammatory, and VLDL-suppression mechanisms co-occur. Icosapent ethyl is FDA-approved for CV risk reduction in TG-elevated high-risk patients on statins.

3. APOC3-targeting: disinhibiting LPL via ApoC-III knockdown

ApoC-III is the dominant endogenous LPL inhibitor. Three approved/late-stage agents target APOC3 mRNA:

Volanesorsen (Waylivra) — 2nd-gen antisense oligonucleotide (ASO). EMA conditionally approved for FCS 2019 (not FDA-approved). In APPROACH trial (n=66 FCS patients; volanesorsen vs placebo): reduced TG ~77% from baseline vs ~18% increase in placebo (p<0.001); mean TG decrease ~1,712 mg/dL in the volanesorsen group. Key safety concern: thrombocytopenia — 15/33 patients (45%) had platelet counts between 50,000–100,000/μL; 2/33 (6%) had severe thrombocytopenia (~25,000/μL); after enhanced platelet monitoring was instituted, no patient had counts below 50,000/μL. The FDA declined approval citing the thrombocytopenia risk. Requires close CBC monitoring. long-term-unknown

Olezarsen (NEJM 2024) — next-generation ASO to APOC3, designed with GalNAc-conjugation for hepatocyte targeting; improved TI vs volanesorsen. In BRIDGE-TIMI 73a (n=154; high CV-risk patients with TG 200–499 mg/dL on statin therapy): 50 mg monthly reduced TG by 49.3 percentage points vs placebo; 80 mg monthly reduced TG by 53.1 percentage points vs placebo; p<0.001 for both. Clinically meaningful thrombocytopenia not observed, in contrast to volanesorsen 2. Phase 3 CV outcomes trial ongoing. Not yet FDA-approved.

Plozasiran (ARO-APOC3) — hepatocyte-targeted siRNA to APOC3 (Arrowhead/Amgen). In PALISADE trial (n=75; FCS patients with persistent chylomicronemia): plozasiran 25 mg Q3M reduced TG by ~80% vs placebo (−17%); 50 mg Q3M reduced TG by ~78%; p<0.001 for both; acute pancreatitis significantly lower (OR 0.17; 95% CI 0.03–0.94; p=0.03) 10. Phase 3 ongoing for severe hypertriglyceridemia. Thrombocytopenia not observed with siRNA modality.

4. ANGPTL3-targeting: dual LPL and PCSK9-independent LDL lowering

Evinacumab (Evkeeza) — anti-ANGPTL3 monoclonal antibody, FDA-approved for homozygous familial hypercholesterolemia (per ldlr page). Mechanistically works by releasing LPL from ANGPTL3 inhibition (→ TG lowering) and by a separate LDL-lowering mechanism independent of ldlr (relevant in HoFH where LDLR function is absent). Provides strong proof-of-concept that pharmacological ANGPTL3 blockade is safe and efficacious. Multiple ANGPTL3 ASO/siRNA approaches (vupanorsen, zodasiran) in development for non-FH hypertriglyceridemia.

Pathway membership

  • lipoprotein-metabolism — LPL is the central effector of TG hydrolysis in both the exogenous (chylomicron) and endogenous (VLDL) sub-pathways
  • atherosclerosis — downstream consequence of impaired LPL-mediated remnant clearance
  • insulin-igf1 — insulin resistance reduces LPL activity in muscle and elevates ApoC-III; LPL activity is partially insulin-sensitive in adipose (stimulatory at physiologic insulin)
  • gpihbp1 — essential anchor; transports LPL to luminal endothelial surface; mutations → FCS-like syndrome
  • apob — structural protein of TG-rich lipoprotein substrates (ApoB-48 on chylomicrons; ApoB-100 on VLDL)
  • apoe — on remnant particles; ligand for hepatic clearance after LPL-mediated TG stripping
  • ldlr — clears VLDL remnants (IDL) after LPL action; central partner in the overall lipoprotein cascade
  • apoc3 — primary endogenous inhibitor; drug target for LPL disinhibition
  • angptl3 — endogenous inhibitor; drug target for combined TG + LDL lowering
  • gpihbp1 — LPL-docking anchor on endothelium

Limitations and gaps

  • #gap/needs-canonical-id — LPL absent from GenAge-human as of 2026-05-09; lipase enzymes are underrepresented in aging databases relative to TFs and kinases.
  • #gap/needs-replication — Age-related decline in LPL activity in specific tissues (muscle vs adipose) is understudied in well-powered human cohorts; most evidence is from small studies or indirect inference.
  • #gap/contradictory-evidence — REDUCE-IT vs STRENGTH EPA/DHA outcome discordance is unresolved: mechanistic differences (EPA-only vs mixed, mineral-oil placebo issue) remain actively debated.
  • #gap/long-term-unknown — APOC3-targeting therapy outcomes beyond 1–2 years, and long-term platelet safety of volanesorsen, are not established.
  • #gap/dose-response-unclear — The optimal LPL-pathway targeting strategy for non-FCS patients with moderate hypertriglyceridemia (TG 200–500 mg/dL) who are already on maximal statins has not been settled by a CV outcomes trial (olezarsen Phase 3 data pending).
  • #gap/no-mechanism — The molecular basis for the modest anti-atherogenic effect of LPL Ser447Stop (gain-of-function truncation of 2 C-terminal aa) remains incompletely understood at the structural level.

Footnotes

Footnotes

  1. doi:10.1056/NEJMoa1812792 · PMID: 30415628 · n=8,179 · rct (REDUCE-IT; icosapent ethyl 4 g/d vs mineral-oil placebo; statin-background; TG inclusion 135–499 mg/dL) · HR 0.75 (95% CI 0.68–0.83) · p<0.001 for MACE reduction (17.2% vs 22.0% event rate) · model: human (high CV-risk; 70.7% secondary prevention) · archive: not_oa (closed access; verified via PubMed abstract PMID 30415628) ↩ ↩2

  2. doi:10.1056/NEJMoa2402309 · n=154 · rct (BRIDGE-TIMI 73a; olezarsen 50 mg or 80 mg monthly vs placebo; high CV-risk patients with TG 200–499 mg/dL on statin therapy) · TG reduction: 49.3 percentage points (50 mg) and 53.1 percentage points (80 mg) vs placebo; p<0.001 · clinically meaningful thrombocytopenia not observed · model: human · archive: not_oa (closed access; verified via PubMed abstract PMID 38587249) ↩ ↩2

  3. doi:10.1194/jlr.r018689 · review (J Lipid Research; thematic review series) · confirms GPIHBP1 expressed exclusively in capillary endothelial cells; LPL synthesized in parenchymal cells (adipocytes/myocytes/cardiomyocytes); GPIHBP1 transports LPL from interstitial space across endothelium to capillary lumen; single Ly6-domain missense mutations in GPIHBP1 can abolish LPL binding → FCS-like phenotype · archive: completed (hybrid OA) ↩

  4. doi:10.1016/s0021-9258(19)39557-2 · in-vitro · 239 citations · demonstrates ApoC-II direct allosteric activation of LPL; modulation by ApoA-IV · Journal of Biological Chemistry ↩

  5. doi:10.1056/NEJMoa1307095 · exome-sequencing + LOF-variant association study (TG and HDL Working Group of the Exome Sequencing Project, NHLBI) · n=110,970 for CHD analysis (34,002 CHD cases + 76,968 controls across 15 studies) · APOC3 LOF carriers (rare missense/splice/nonsense variants; ~1 in 150 persons): ~39% lower TG combined (42% European ancestry), ~40% lower CHD risk (OR 0.60; 95% CI 0.47–0.75; P<0.001) · study design: LOF variant discovery in 3,734 exomes + replication in 41,671 → CHD association in 110,970 (NOT a Mendelian randomization study) · model: human · archive: completed ↩ ↩2

  6. doi:10.1074/jbc.m808477200 · in-vitro · mechanistic · Journal of Biological Chemistry · characterizes distinct inhibitory mechanisms of ANGPTL3 (inhibits LPL catalytic activity) vs ANGPTL4 (induces LPL dimer dissociation → inactive monomers) · 135 citations · archive: pending (hybrid OA) ↩ ↩2

  7. doi:10.3390/ijerph14010084 · meta-analysis (14 case-control studies; n=1,519 CAD cases, 824 controls for Ser447X analysis) · LPL Ser447X polymorphism and coronary artery disease risk · key finding: X allele carrier model showed no significant CAD association (OR 1.04, 95% CI 0.60–1.80, p=0.90, I²=87%); XX homozygote genotype associated with increased CAD risk (OR 2.37, 95% CI 1.33–4.24, p=0.004, I²=53%; publication bias noted) · gold OA · archive: completed ↩

  8. The REDUCE-IT vs STRENGTH debate: mineral oil placebo in REDUCE-IT may have raised LDL-C ~11 mg/dL in placebo arm, inflating apparent benefit of icosapent ethyl. Counter-argument: even adjusting for LDL change, a significant residual benefit persists. No consensus as of 2026-05-09. contradictory-evidence ↩

  9. doi:10.1001/jama.2020.22258 · n=13,078 · rct (STRENGTH primary publication; Nicholls SJ et al.; EPA+DHA omega-3 CA 4 g/d vs corn oil; statin-background; median baseline TG ~240 mg/dL) · HR 0.99 (95% CI 0.90–1.09) · p=0.84 (null result for MACE; trial terminated early for futility) · model: human (high CV-risk) · Note: a secondary analysis of achieved EPA/DHA levels in STRENGTH (doi:10.1001/jamacardio.2021.1157; Nissen et al.; archive: green OA via PMC8126992) also showed neutral HR 0.98 at top EPA tertile; discordance with REDUCE-IT may reflect EPA vs DHA pharmacology, mineral-oil-vs-corn-oil placebo effects, or both contradictory-evidence ↩

  10. doi:10.1056/NEJMoa2409368 · n=75 · rct (PALISADE; plozasiran 25 mg or 50 mg Q3M [every 3 months] vs placebo; persistent chylomicronemia patients) · TG reduction ~80% (25 mg) and ~78% (50 mg) vs placebo (−17%); p<0.001 · acute pancreatitis significantly lower (OR 0.17; 95% CI 0.03–0.94; p=0.03) · model: human (persistent chylomicronemia) · archive: not_oa (closed access; verified via PubMed abstract PMID 39225259) ↩

Graph View

Backlinks